Business Segment, Geographic, and Concentration Risk Information (Tables)

6 Months Ended

Jun. 30, 2017

Segment Reporting [Abstract]

Summary of Segment Information

Segment information is as follows (in thousands):

	Three Months Ended June 30,						Six Months Ended June 30,
	2017			2016			2017			2016
	(unaudited)						(unaudited)
Net (loss) income attributable to Athenex, Inc.:
Oncology Innovation Platform	$	(33,018	)	$	(12,037	)	$	(61,277	)	$	(22,452	)
Global Supply Chain Platform		(1,981	)		428			(3,129	)		225
Commercial Platform		(3,626	)		(812	)		(15,207	)		(812	)
Total consolidated net loss attributable to Athenex, Inc.	$	(38,625	)	$	(12,421	)	$	(79,613	)	$	(23,039	)

Summary of Revenue by Segments

	Three Months Ended June 30,						Six Months Ended June 30,
	2017			2016			2017			2016
	(unaudited)						(unaudited)
Total revenue:
Oncology Innovation Platform	$	270		$	404		$	1,003		$	546
Global Supply Chain Platform		4,509			6,249			10,806			11,605
Commercial Platform		1,820			-			1,896			-
Total revenue for reportable segments		6,599			6,653			13,705			12,151
Intersegment revenue		(2,004	)		(1,460	)		(4,529	)		(2,329	)
Total consolidated revenue	$	4,595		$	5,193		$	9,176		$	9,822

Summary of Revenue by Product Group

	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
	(unaudited)				(unaudited)
Total revenue by product group:
API sales	$	2,024	$	3,726	$	5,023	$	7,688
Medical device sales		232		519		567		876
Contract manufacturing revenue		247		544		684		712
Commercial product sales		1,913		31		2,042		32
License fees and consulting revenue		98		71		696		166
Grant revenue		81		302		164		348
Total consolidated revenue	$	4,595	$	5,193	$	9,176	$	9,822

Summary of Depreciation, Amortization and Assets by Segment

	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
	(unaudited)				(unaudited)
Total depreciation and amortization:
Oncology Innovation Platform	$	120	$	51	$	212	$	98
Global Supply Chain Platform		495		284		1,021		654
Commercial Platform		233		-		431		-
Total consolidated depreciation and amortization	$	848	$	335	$	1,664	$	752

	June 30,		December 31,
	2017		2016
	(unaudited)
Total assets:
Oncology Innovation Platform	$	97,562	$	53,022
Global Supply Chain Platform		47,052		48,560
Commercial Platform		13,200		4,308
Total consolidated assets	$	157,814	$	105,890

Summary of Revenue by Geographical Segment

	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
	(unaudited)				(unaudited)
Total revenue:
United States	$	2,227	$	1,011	$	2,940	$	1,513
India		790		1,252		2,261		3,208
Austria		716		1,792		1,718		3,184
China		417		655		729		1,111
Taiwan		-		-		500		-
Other foreign countries		445		483		1,028		806
Total consolidated revenue	$	4,595	$	5,193	$	9,176	$	9,822

Summary of Property and Equipment by Geographical Segment

	June 30,		December 31,
	2017		2016
	(unaudited)
Total property and equipment, net:
United States	$	4,280	$	2,177
China		4,041		3,633
Total consolidated property and equipment, net	$	8,321	$	5,810

Summary of Customer Revenue and Accounts Receivable Concentration

Customer revenue and accounts receivable concentration amounted to the following for the identified periods. All customers relate to the Global Supply Chain Platform Segment.

	Three Months Ended June 30,						Six Months Ended June 30,
	2017			2016			2017			2016
	(unaudited)						(unaudited)
Percentage of total revenue by customer:
Customer A		17	%		24	%		22	%		33	%
Customer B		15	%		31	%		18	%		31	%

	June 30,			December 31,
	2017			2016
	(unaudited)
Percentage of total accounts receivable by customer:
Customer A		19	%		50	%
Customer B		9	%		9	%